Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done.

Learn more at novonordisk.com/about-novo-nordisk

Innovative medicine is our key contribution
Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aim to lead in all disease areas in which we are active. In 2018, Novo Nordisk invested 13.2% of its sales in R&D, and around 25,000 people took part in 127 clinical trials across approximately 4,800 clinical sites globally. Our current pipeline includes new insulins and GLP-1 analogues, and new treatments for obesity, haemophilia and other serious chronic diseases.

Learn more at novonordisk.com > research and development

Changing lives with devices
We strive to develop delivery devices that ease the burden, and meet the diverse needs, of millions of people living with serious chronic diseases. We do this by combining patient insight with engineering excellence to design our injection pens and needles. In diabetes, we provide a broad range of innovative durable and prefilled insulin and GLP-1 pens. In parallel, we are designing and developing the next generation of delivery systems, including connected devices. We also provide injection devices for the treatment of obesity and growth disorders.

Learn more at novonordisk.com/patients

Triple Bottom Line approach to business
To ensure we continue helping people affected by serious chronic diseases, our business needs to grow both profitably and responsibly. We call this approach the Triple Bottom Line. It means Novo Nordisk is committed to considering the financial, social and environmental impacts of every decision as we work to create value for individuals, society and investors.

Learn more at novonordisk.com > sustainable business

Unique ownership structure
The Novo Nordisk Foundation is Novo Nordisk’s main shareholder. The foundation’s purpose is to provide a stable basis for the commercial and research activities of the Novo Group of companies, and also to support scientific and humanitarian projects. This unique ownership structure enables long-term planning and ensures that the company remains in Danish ownership.

Learn more at novonordiskfonden.dk/en
Novo Nordisk engages with patients, healthcare professionals and other stakeholders to drive change.

**ACTIONS THAT DRIVE CHANGE**

Producing life-saving medicine is a significant responsibility; however, it takes more to defeat serious chronic diseases. That is why we work in partnerships with patients, policymakers, healthcare professionals and non-governmental organisations to raise awareness, improve prevention, promote earlier diagnosis and expand access to care.

**Cities Changing Diabetes**

Cities Changing Diabetes is a partnership programme bringing together global and local partners with the aim of putting ‘urban diabetes’ at the top of healthcare agendas and on the agenda of those designing and managing cities for the future. Learn more at citieschangingdiabetes.com

**World Diabetes Day, World Obesity Day and World Haemophilia Day**

Every year, together with international and local diabetes, obesity and haemophilia organisations, Novo Nordisk unites the world around awareness-raising activities. Learn more at novonordisk.com/wdd and novonordisk.com/whd

**The World Diabetes Foundation and Novo Nordisk Haemophilia Foundation**

Novo Nordisk has established the World Diabetes Foundation and Novo Nordisk Haemophilia Foundation with the aim of expanding access to diabetes and haemophilia care in less-developed countries. Learn more at worlddiabetesfoundation.org and nnhf.org

**ACTION Study**

The Awareness, Care and Treatment in Obesity Management – an International Observation (ACTION IO) Study is the first international study to investigate barriers to obesity management among people with obesity and healthcare professionals in 11 countries worldwide. The ACTION Study has previously been conducted in the US and Canada. Learn more at actionstudy.com

**Embracing a circular mindset**

Our environmental strategy, Circular for Zero, sets an ambitious direction for our organisation: to have zero environmental impact. To get there we are embracing a circular mindset – designing and producing our products so that they can be recovered and reused, and reshaping our business practices to minimise consumption and eliminate waste by turning it into new resources. Learn more at novonordisk.com > sustainable business > zero environmental impact

**Team Novo Nordisk**

Team Novo Nordisk is a global all-diabetes sports team spearheaded by the world’s first all-diabetes professional cycling team. Their mission is to inspire, educate and empower people affected by diabetes. Learn more at teamnovonordisk.com

**FOLLOW US**

facebook.com/novonordisk  linkedin.com/company/novo-nordisk  instagram.com/novonordisk  twitter.com/novonordisk  youtube.com/novonordisk